Glioblastoma — biological & vaccine options
18 open options
- EXPANDED ACCESSAVAILABLE
Glioblastoma and Individualized Therapies
Vaccination — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
Biospecimen Collection · Eflornithine · Lumbar Puncture — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
Autologous dual-target CAR-T cells selected from the predefined target library. · Fludarabine · Cyclophosphamide — 1 site
- TRIALPHASE1RECRUITING
Intracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive Glioblastoma
NK-92/5.28.z · Ezabenlimab — 5 sites
- TRIALPHASE2RECRUITING
Injection of Active Allogeneic Natural Killer Cells in Patients With Gliomas
NK cell therapy — 1 site
- TRIALPHASE1 / PHASE2NOT_YET_RECRUITING
Effect of Cytokine-induced Killer Cells for Stage I-II Malignant Gliomas
Temozolomide · CIK
- TRIALPHASE2RECRUITING
Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma
Bevacizumab · Biospecimen Collection · Computed Tomography — 3 sites
- TRIALPHASE2RECRUITING
Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors
DNX-2401 — 2 sites
- TRIALPHASE1RECRUITING
Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas
Autologous Anti-EGFR/Anti-IL13Ralpha2 CAR T-cells · Biopsy Procedure · Biospecimen Collection — 1 site
- TRIALPHASE1RECRUITING
Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas
Anti-GARP Chimeric Antigen Receptor-T Cells · Biospecimen Collection · Chest Radiography — 1 site
- TRIALNANOT_YET_RECRUITING
Correlative Analysis Between Magnetic Resonance Spectroscopy (MRS) and Essential Clinicobiological Data in Glioblatoma Multiforme (GBM)
MRS study · blood samples — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
Near-Infrared Fluorescence Imaging · Panitumumab · Panitumumab-IRDye800 — 1 site
- TRIALEARLY_PHASE1RECRUITING
PET-imaging of Two Vartumabs in Patients With Solid Tumors
89Zr-DFO-N-Suc-F8scFv · 89Zr-DFO-N-Suc-C9scFv · PET/CT scan — 1 site
- TRIALPHASE1RECRUITING
Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
Dual-target CAR-NK cells · Cyclophosphamide · Fludarabine — 1 site
- TRIALPHASE1RECRUITING
Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells
E-SYNC T Cells · Cyclophosphamide (non-investigational) · Fludarabine (non-investigational) — 1 site
- TRIALPHASE2RECRUITING
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
DOC1021 · Tumor resection · Temodar (Temozolomide) — 18 sites
- TRIALEARLY_PHASE1NOT_YET_RECRUITING
Clinical Study of Allogeneic Vγ9Vδ2 T Cells in the Treatment of Brain Malignant Glioma
Vγ9Vδ2 T cell — 1 site
- TRIALPHASE1RECRUITING
BC008-1A Injection for Recurrent CNS WHO G4 Glioma
BC008-1A · BC008-1A — 1 site
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.